High anti-EBNA-1 IgG levels are associated with early-onset myasthenia gravis

European Journal of Neurology

Volumn 19, Issue 6, 2012, Pages 842-846

  Csuka, D ^a   Banati, M ^b   Rozsa, C ^c   Fust G ^a   Illes, Z ^b  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c Jahn Ferenc Del Pesti korhaz Budapest   (Hungary)

Author keywords

AchR; EBNA; EBV; Myasthenia gravis; Thymoma

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; EPSTEIN BARR VIRUS ANTIGEN 1; IMMUNOGLOBULIN G;

ADULT; ANTIBODY TITER; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; THYMECTOMY; THYMOMA; THYMUS ATROPHY; THYMUS HYPERPLASIA;

ADULT; AGED; DISABILITY EVALUATION; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HUMANS; HUNGARY; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MUSCLE PROTEINS; MYASTHENIA GRAVIS; PROTEIN KINASES; RECEPTORS, CHOLINERGIC; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 84860916035     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03636.x     Document Type: Article

References (18)

1. Niller HH, Wolf H, Minarovits J. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. Semin Cancer Biol 2009; 19: 158-164.
2. Tsuchiya S. Diagnosis of Epstein-Barr virus-associated diseases. Crit Rev Oncol Hematol 2002; 44: 227-238.
3. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009; 8: 475-490.
4. Pal J, Rozsa C, Komoly S, et al. Clinical and biological heterogeneity of autoimmune myasthenia gravis. J Neuroimmunol 2011; 231: 43-54.
5. Cavalcante P, Serafini B, Rosicarelli B, et al. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol 2010; 67: 726-738.
6. Gilhus NE, Owe JF, Hoff JM, et al. Myasthenia gravis: a review of available treatment approaches. Autoimmune Dis 2011; 2011: 847393.
7. Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology 2000; 11: 220-224.
8. Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001; 286: 3083-3088.
9. Levin LI, Munger KL, Rubertone MV, et al. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005; 293: 2496-2500.
10. Farrell RA, Antony D, Wall GR, et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 2009; 73: 32-38.
11. De Jager PL, Simon KC, Munger KL, et al. Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 2008; 70: 1113-1118.
12. Munger K, Levin L, O'Reilly E, et al. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 2011; 17: 1185-1193.
13. McClain MT, Rapp EC, Harley JB, et al. Infectious mononucleosis patients temporarily recognize a unique, cross-reactive epitope of Epstein-Barr virus nuclear antigen-1. J Med Virol 2003; 70: 253-257.
14. Ferrell PB, Aitcheson CT, Pearson GR, et al. Seroepidemiological study of relationships between Epstein-Barr virus and rheumatoid arthritis. J Clin Invest 1981; 67: 681-687.
15. Bhibhatbhan A, Kline G, Vincent A, et al. Anti-MuSK myasthenia gravis presenting with Epstein-Barr virus-associated mononucleosis and immune-mediated diabetes mellitus. Muscle Nerve 2007; 36: 264-266.
16. Tindall RS, Cloud R, Luby J, et al. Serum antibodies to cytomegalovirus in myasthenia gravis: effects of thymectomy and steroids. Neurology 1978; 28: 273-277.
17. Kang I, Quan T, Nolasco H, et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol 2004; 172: 1287-1294.
18. Meyer M, Hols AK, Liersch B, et al. Lack of evidence for Epstein-Barr virus infection in myasthenia gravis thymus. Ann Neurol 2011; 70: 515-518.